

# PRESENTATION SCHEDULE

## Poster Discussion Sessions

(Available on demand from **Friday, May 29** 8AM ET/7AM CST)

### Session: Breast Cancer – Metastatic

Randomized phase III trial of eribulin (E) versus standard weekly paclitaxel (P) as first- or second-line therapy for locally recurrent or metastatic breast cancer (MBC).

**Authors** Minetta C. Liu...**Gini F. Fleming**...Amylou C. Dueck

**Abstract** 1016 • 101

### Session: Genitourinary Cancer – Kidney and Bladder

Safety and preliminary efficacy of rogaratinib in combination with atezolizumab in a phase Ib/II study (FORT-2) of first-line treatment in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and *FGFR* mRNA overexpression.

**Authors** Jonathan E. Rosenberg...**Randy F. Sweis**.

**Abstract** 5014 • 83

### Session: Genitourinary Cancer – Prostate, Testicular, and Penile

TRANSFORMER: Bipolar androgen therapy (BAT) versus enzalutamide (E) for castration-resistant metastatic prostate cancer (mCRPC).

**Authors** Samuel R. Denmeade...**Russell Zelig Szmulewitz**...Emmanuel S. Antonarakis.

**Abstract** 5517 • 98

### Session: Pediatric Oncology

Comparison of chemotherapy dose intensity for AYAs on COG AALL1131 versus CALGB 10403.

**Authors** **Jennifer Lynn McNeer**...**Richard A. Larson**...**Wendy Stock**...Elizabeth A. Raetz.

**Abstract** 10520 • 407

### Session: Pediatric Oncology

Outcomes and toxicities in patients (pts) non-randomly assigned to immunotherapy Children's Oncology Group (COG) ANBL0032.

**Authors** **Ami Vijay Desai**...**Susan Lerner Cohn**...Alice L. Yu.

**Abstract** 10523 • 410

### Session: Head and Neck Cancer

Combination of monalizumab and cetuximab in recurrent or metastatic head and neck cancer patients previously treated with platinum-based chemotherapy and PD-(L)1 inhibitors.

**Authors** Roger B. Cohen...**Alexander T. Pearson**...Jerome Fayette.

**Abstract** 6516 • 177

### Session: Hematologica Malignancies – Plasma Cell Dyscrasia

Measurable residual disease (MRD) assessed by mass spectrometry (MS) in peripheral blood versus next generation sequencing (NGS) in bone marrow in multiple myeloma treated on phase II trial of KRd+ASCT

**Authors** Benjamin Avi Derman...**Jagoda Jasielec**, **Andrzej J. Jakubowiak**.

**Abstract** 8513 • 413

### Session: Hematologic Malignancies – Leukemia, Myelodysplastic Syndromes, and Allotransplant

Long-term survivors and gilteritinib safety beyond one year in *FLT3*-mutated R/R AML: ADMIRAL trial follow-up.

**Authors** Alexander E. Perl...**Richard A. Larson**...Erkut Bahceci.

**Abstract** 7514 • 287

## Symposia Oral Abstracts

(Available on demand from **Friday, May 29** 8AM ET/7AM CST)

### Session: Breast Cancer—Local/Regional/Adjuvant

ALTERNATE: Neoadjuvant endocrine treatment (NET) approaches for clinical stage II or III estrogen receptor-positive HER2-negative breast cancer (ER+ HER2- BC) in postmenopausal (PM) women: Alliance A011106.

**Authors** Cynthia X. Ma...**Olwen Mary Hahn**...Matthew James Ellis.

**Abstract** 504

### Session: Breast Cancer—Metastatic

Tbcrc 048: a phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in dna damage response (DDR) pathway genes (olaparib expanded).

**Authors** Nadine M. Tung...**Rita Nanda**...Judy Ellen Garber.

**Abstract** 1002

### Session: Breast Cancer - Local/Regional/Adjuvant

*Steps Forward and Lessons Learned: Using Biomarkers to Guide Targeted Therapies in Breast Cancer, The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium supported by the Breast Cancer Research Foundation®.*

A multiparameter classifier to predict response to lapatinib plus trastuzumab (It) without chemotherapy in her2+ breast cancer (bc).

**Authors** Jamunarani Veeraraghavan...**Rita Nanda**...Mothaffar F. Rimawi.

**Abstract** 1011

### Session: Central Nervous System Tumors

Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL).

**Authors** Antonio Marcilio...**Theodore Karrison**...Minesh P. Mehta.

**Abstract** 2501

### Session: Hematologic Malignancies—Plasma Cell Dyscrasia

Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).

**Authors** Sham Mailankody, **Andrzej J. Jakubowiak**...Kuan Wong.

**Abstract** 8504

### Session: Hematologic Malignancies—Plasma Cell Dyscrasia

Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.

**Authors** Jesus G. Berdej...**Andrzej J. Jakubowiak**, Sundar Jagannath.

**Abstract** 8505

### Session: Learning from the Biology: Advances in Endometrial and Ovarian Cancer

A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.

**Authors** Stephanie Lheureux...**Gini F. Fleming**.

**Abstract** 6010

### Session: Developmental Therapeutics—Immunotherapy

A phase I, first-in-human, open-label, dose-escalation study of MGD013, a bispecific DART molecule binding PD-1 and LAG-3, in patients with unresectable or metastatic neoplasms.

**Authors** Jason J. Luke...**Hedy L. Kindler**...George Blumenschein.

**Abstract** 3004

## Symposia Oral Abstracts (Continued)

### Session: Melanoma/Skin Cancers

Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on pd1 ab in melanoma (MEL) in a phase ii trial.

**Authors** Daniel Olson...**Theodore Karrison**...**Thomas Gajewski**, Nikhil I. Khushalani.

**Abstract** 10004

### Session: Pediatric Oncology I

Randomized phase II trial of MIBG versus MIBG/vincristine/irinotecan versus MIBG/vorinostat for relapsed/refractory neuroblastoma: A report from the New Approaches to Neuroblastoma Therapy Consortium.

**Authors** Steven G. DuBois...**Susan Lerner Cohn**...Katherine K. Matthay.

**Abstract** 10500

### Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

PrEO505: Phase II multicenter study of anti-PD-L1, durvalumab, in combination with cisplatin and pemetrexed for the first-line treatment of unresectable malignant pleural mesothelioma (MPM)—A PrECOG LLC study.

**Authors** Patrick M. Forde...**Hedy L. Kindler**...Suresh S. Ramalingam.

**Abstract** 9003

### Session: Drug Development for Rare Mutations: The Opportunity to Unite and Conquer!

Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.

**Authors** **Ami Vijay Desai**...Elizabeth Fox.

**Abstract** 107

### Session: MET Mutations: The Meat of the Matter

Safety and preliminary clinical activity of the MET antibody mixture, Sym015 in advanced non-small cell lung cancer (NSCLC) patients with MET amplification/exon 14 deletion ( $MET^{Amp/Ex14\Delta}$ ).

**Authors** D. Ross Camidge...**Daniel V.T. Catenacci**...Enriqueta Felip.

**Abstract** 9510

### Session: Genitourinary Cancer—Kidney and Bladder

Optimized management of nivolumab (Nivo) and ipilimumab (Ipi) in advanced renal cell carcinoma (RCC): A response-based phase II study (OMNIVORE).

**Authors** Rana R. McKay...**Walter Michael Stadler**...Toni K. Choueiri.

**Abstract** 5005

### Session: Genitourinary Cancer—Kidney and Bladder

Tumor, immune, and stromal characteristics associated with clinical outcomes with atezolizumab (atezo) + platinum-based chemotherapy (PBC) or atezo monotherapy (mono) versus PBC in metastatic urothelial cancer (mUC) from the phase III IMvigor130 study.

**Authors** Matt D. Galsky...**Peter H. O'Donnell**...Sanjeev Mariathasan.

**Abstract** 5011

### Session: Genitourinary Cancer—Kidney and Bladder

IMvigor010: Primary analysis from a phase III randomized study of adjuvant atezolizumab (atezo) versus observation (obs) in high-risk muscle-invasive urothelial carcinoma (MIUC).

**Authors** Maha H. A. Hussain...**Peter H. O'Donnell**...Joaquim Bellmunt.

**Abstract** 5000

## Publication Only

### Session: Publication Only: Sarcoma

Prediction of histologic and molecular subsets of soft tissue sarcoma using deep learning.

**Authors** Ari Rosenberg...Alexander T. Pearson.

**Abstract** e23529

### Session: Publication Only: Symptoms and Survivorship

Evaluation of prescribing practices of denosumab and zoledronic acid in breast and prostate cancer patients at University of Chicago Medicine.

**Authors** Heng Yang...Walter Michael Stadler.

**Abstract** e24144

### Session: Publication Only: Care Delivery and Regulatory Policy

Impact of an oncology clinical pharmacist specialist in an outpatient multiple myeloma clinic.

**Authors** Amin Virani...Andrzej J. Jakubowiak, Jagoda Jasielec...Sandeep Parsad.

**Abstract** e14030

### Session: Publication Only: Genitourinary Cancer—Prostate, Testicular, and Penile

Expansion of germline genetic testing criteria for prostate cancer yields findings across all stages of disease.

**Authors** Sarah M. Nielsen, Russell Zelig Szmulewitz...Edward D. Esplin.

**Abstract** e17615

### Session: Publication Only: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

POLO: Radiologic assessment of the impact of maintenance olaparib in patients (pts) with metastatic pancreatic cancer (mPaC).

**Authors** Lawrence Howard Schwartz, Hedy L. Kindler...Talia Golan.

**Abstract** e16800

### Session: Publication Only: Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Toxicity burden in older patients with chronic lymphocytic leukemia (CLL) receiving bendamustine with rituximab (BR) or ibrutinib (IB) regimens: Alliance A041202.

**Authors** Amy S. Ruppert...Richard A. Larson...Jennifer Ann Woyach.

**Abstract** e20004

## Posters

(Available on demand from **Friday, May 29** 8AM ET/7AM CST)

### Session: Improving cancer pain control: Potential impact of CYP2D6 pharmacogenomic (PGx) testing in oncology (Onc) patients.

Symptoms and Survivorship

**Author(s)** Natalie Reizine...Mark J. Ratain, Peter H. O'Donnell.

**Abstract / POSTER** 12089 • 377

### Session: Using sequential next-generation sequencing assays to identify germline cancer predisposition variants.

Cancer Prevention, Risk Reduction, and Genetics

**Author(s)** Ira Lignugaris Kraft...Jeremy Segal, Lucy A. Godley.

**Abstract / POSTER** 1581 • 73

## Posters (Continued)

**Session: Dose and volume de-escalation for HPV-associated oropharyngeal cancer: Long-term follow-up of the OPTIMA trial.**

Head and Neck Cancer

**Author(s)** Ari Rosenberg, Nishant Agrawal, Alexander T. Pearson...Elizabeth A. Blair...Mark W. Lingen, Daniel J. Haraf, Everett E. Vokes.

Abstract / POSTER 6575 • 236

**Session: Personalized antibodies for gastroesophageal adenocarcinoma (PANGEA): Secondary and final primary efficacy analyses.**

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Author(s)** Daniel V.T. Catenacci...Chih-Yi Liao...John Hart...Yuan Ji, Theodore Karrison, Blase N. Polite, Hedy L. Kindler.

Abstract / POSTER 4561 • 169

**Session: Randomized phase I trial to evaluate Concurrent or Sequential Ipilimumab, Nivolumab, and stereotactic body Radiotherapy in patients with stage IV non-small cell lung cancer (COSINR Study).**

Lung Cancer—Non-Small Cell Metastatic

**Author(s)** Jyoti D. Patel, Christine M. Bestvina, Theodore Karrison...Philip C. Hoffman, Sean P. Pitroda, Everett E. Vokes, Steven J. Chmura.

Abstract / POSTER 9616 • 382

**Session: Morphologic and molecular analysis of early-onset gastroesophageal adenocarcinomas.**

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Author(s)** Namrata Setia...Sonia Kupfer, John Hart, Daniel V.T. Catenacci.

Abstract / POSTER 4547 • 155

**Session: Assessment of FcgRIIIA single nucleotide polymorphisms (SNPs) on the efficacy of IgG1 monoclonal antibodies (mAbs) in PANGEA study patients (pts) with advanced gastroesophageal adenocarcinoma (aGEA).**

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Author(s)** Anthony Serritella...Daniel V.T. Catenacci.

Abstract / POSTER 4526 • 134

**Session: Assessing the effect of immunosuppressive agents for immune-related adverse event management on tumor response.**

Developmental Therapeutics—Immunotherapy

**Author(s)** Pankti Reid...Thomas Gajewski.

Abstract / POSTER 3066 • 130

**Session: Detection of somatic mutations in saliva of patients with oral cavity squamous cell carcinoma.**

Head and Neck Cancer

**Author(s)** Evgeny Izumchenko...Mark W. Lingen, Nishant Agrawal.

Abstract / POSTER 6562 • 223

**Session: Evaluation of spatiotemporal heterogeneity of PDL1 expression in gastroesophageal adenocarcinoma (GEA) at baseline diagnosis and after chemotherapy.**

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Author(s)** Katherine I. Zhou...Daniel V.T. Catenacci.

Abstract / POSTER 4528 • 136

**Session: Evaluation of spatiotemporal heterogeneity of tumor mutational burden (TMB) in gastroesophageal adenocarcinoma (GEA) at baseline diagnosis and after chemotherapy.**

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Author(s)** Katherine I. Zhou...Daniel V.T. Catenacci.

Abstract / POSTER 4546 • 154

## Posters (Continued II)

**Session: Machine learning guided adjuvant treatment of head and neck cancer.**

Head and Neck Cancer

**Author(s)** Frederick Howard...**Michael T. Spiotto, Alexander T. Pearson.**

**Abstract / POSTER** 6567 • 228

**Session: Clinical and genetic risk factors for radiation-associated ototoxicity: A report from the childhood cancer survivor study and the St. Jude Lifetime Cohort.**

Pediatric Oncology

**Author(s)** Matthew R. Trendowski...**M. Eileen Dolan.**

**Abstract / POSTER** 10550 • 437

**Session: Phase I study of NBTXR3 activated by radiotherapy in patients with advanced cancers treated with an anti-PD-1 therapy.**

Developmental Therapeutics—Immunotherapy

**Author(s)** Colette Shen...**Alexander T. Pearson**...Tanguy Y. Seiwert.

**Abstract / POSTER** TPS3173 • 237

**Session: Phase II trial of guadecitabine priming and pembrolizumab in platinum resistant recurrent ovarian cancer.**

Gynecologic Cancer

**Author(s)** Daniela Matei...**John William Moroney, Gini F. Fleming**...Bin Zhang.

**Abstract / POSTER** 6025 • 196

**Session: Outcome in patients with refractory high-risk neuroblastoma.**

Pediatric Oncology

**Author(s)** Amir Bari Siddiqui...**Susan Lerner Cohn, Ami Vijay Desai.**

**Abstract / POSTER** 10537 • 424

**Session: Final results of controlled IL-12 monotherapy in adults with grade III or IV gliomas.**

Developmental Therapeutics—Immunotherapy

**Author(s)** E. Antonio Chiocca...**Bakhtiar Yamini**...Laurence JN Cooper.

**Abstract / POSTER** 3040 • 104

**Session: SGN228-001: A phase I open-label dose-escalation, and expansion study of SGN-CD228A in select advanced solid tumors.**

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

**Author(s)** Amita Patnaik, **Hedy L. Kindler**...Ani Sarkis Balmanoukian.

**Abstract / POSTER** TPS3652 • 382

**Session: Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence.**

Breast Cancer—Local/Regional/Adjuvant

**Author(s)** Hope S. Rugo...**Rita Nanda**...Binghe Xu.

**Abstract / POSTER** TPS599 • 91

**Session: Phase I study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).**

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Author(s)** Andrew L. Coveler...**Hedy L. Kindler**...Martin Gutierrez.

**Abstract / POSTER** TPS4671 • 279

## Posters (Continued III)

**Session: PFS by blinded independent central review (BICR) in the VELIA trial of veliparib (V) plus carboplatin/paclitaxel (CP) and as monotherapy in newly diagnosed patients (pts) with high-grade serous ovarian cancer (HGSC).**

Gynecologic Cancer

**Author(s)** Carol Aghajanian...**Gini F. Fleming**...Robert L. Coleman.

**Abstract / POSTER** 6077 • 248

**Session: SGNLVA-001: A phase I open-label dose escalation and expansion study of SGN-LIV1A administered weekly in breast cancer.**

Breast Cancer—Metastatic

**Author(s)** Heather Christine Beckwith...**Rita Nanda**...Howard A. Burris III.

**Abstract / POSTER** TPS1104 • 189

**Session: ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.**

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

**Author(s)** Jacob Sands...**Everett E. Vokes**...Tom Stinchcombe.

**Abstract / POSTER** TPS9077 • 270

**Session: Impact of frontline doublet versus triplet therapy on clinical outcomes: Exploratory analysis from the RAINBOW study.**

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Author(s)** Samuel J Klemptner...**Daniel V.T. Catenacci**...Atsushi Ohtsu.

**Abstract / POSTER** 4543 • 151

**Session: Impact of relacorilant, a selective glucocorticoid receptor antagonist, on the immunosuppressive effects of endogenous cortisol.**

Developmental Therapeutics—Immunotherapy

**Author(s)** Andrew Greenstein...**Gini F. Fleming**...Stacie Peacock Shepherd.

**Abstract / POSTER** 3091 • 155

**Session: POLO: Quality-adjusted (QA) progression-free survival (PFS) and patient (pt)-centered outcomes with maintenance olaparib in pts with metastatic pancreatic cancer (mPaC).**

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Author(s)** Hyun Kyoo Yoo, **Hedy L. Kindler**...Talia Golan.

**Abstract / POSTER** 4626 • 234

**Session: Olaparib sensitivity observed in metastatic pancreatic cancer (mPaC) with a wide spectrum of germline BRCA1 and BRCA2 mutations (gBRCAm).**

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Author(s)** Talia Golan, **Hedy L. Kindler**...Yu-Zhen Liu.

**Abstract / POSTER** 4621 • 229

**Session: Abbreviated geriatric assessment (GA) in new oncology patients and its association with early death.**

Symptoms and Survivorship

**Author(s)** Michael Maranzano...**Blase N. Polite**, Selina Lai-ming Chow.

**Abstract / POSTER** 12035 • 323

**Session: Phase I study of the antibody-drug conjugate ABBV-321 in patients with non-small cell lung cancer and squamous head and neck cancer with overexpression of the epidermal growth factor receptor.**

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

**Author(s)** Benedito A. Carneiro, **Christine M. Bestvina**...Kyriakos P. Papadopoulos.

**Abstract / POSTER** TPS3649 • 379

## Posters (Continued IV)

**Session: Phase II, open-label, randomized study of first-line zolbetuximab plus gemcitabine and nab-paclitaxel (GN) in Claudin 18.2-positive metastatic pancreatic cancer (mPC).**

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Author(s)** Wungki Park...**Hedy L. Kindler**.

**Abstract / POSTER** TPS4667 • 275

**Session: Phase I/II dose-escalation and expansion study of FLX475 alone and in combination with pembrolizumab in advanced cancer.**

Developmental Therapeutics—Immunotherapy

**Author(s)** John D. Powderly...**Daniel V.T. Catenacci**...William Ho.

**Abstract / POSTER** TPS3163 • 227

**Session: KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).**

Breast Cancer—Local/Regional/Adjuvant

**Author(s)** Hope S. Rugo...**Rita Nanda**...Vassiliki Karantza.

**Abstract / POSTER** TPS596 • 88

**Session: Efficacy of enzalutamide (ENZA) + androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) by pattern of metastatic spread: ARCHES post hoc analyses.**

Genitourinary Cancer—Prostate, Testicular, and Penile

**Author(s)** Neal D. Shore...**Russell Zelig Szmulewitz**...Arnulf Stenzl.

**Abstract / POSTER** 5547 • 128

**Session: CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC).**

Breast Cancer—Local/Regional/Adjuvant

**Author(s)** Valentina Boni...**Randy F. Sweis**...Funda Meric-Bernstam.

**Abstract / POSTER** 526 • 18

**Session: Immunotherapy and chemotherapy combination for chest wall disease: TBCRC 044 trial.**

Breast Cancer—Metastatic

**Author(s)** Neelima Vidula, **Rita Nanda**...Hope S. Rugo.

**Abstract / POSTER** TPS1114 • 199

**Session: KITE-439: A phase I study of HPV16 E7 T cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers.**

Developmental Therapeutics—Immunotherapy

**Author(s)** Kedar Kirtane...**Michael Russell Bishop**...A. Scott Jung.

**Abstract / POSTER** TPS3149 • 213

**Session: Phase III study of first-line zolbetuximab + CAPOX versus placebo + CAPOX in Claudin 18.2<sup>+</sup>/HER2<sup>-</sup> advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: GLOW.**

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

**Author(s)** Manish A. Shah...**Daniel Catenacci**...Rui-hua Xu.

**Abstract / POSTER** TPS4648 • 256



## Posters (Continued V)

**Session: Phase Ib trial combining rapid determination of drug-drug interaction (DDI) followed by a dose finding period to assess safety and preliminary efficacy of fimepinostat plus venetoclax in patients with aggressive B-cell lymphoma.**

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

**Author(s)** Tycel Jovelle Phillips...**Sonali M. Smith**...Connie Lee Batlevi.

**Abstract / POSTER** 8056 • 389

**Session: Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.**

Breast Cancer—Metastatic

**Author(s)** Patricia LoRusso...**Rita Nanda**...Kurt A. Schalper.

**Abstract / POSTER** TPS1102 • 187

**Session: Radium-223 (Rad) and niraparib (Nira) treatment (tx) in castrate-resistant prostate cancer (CRPC) patients (pts) with and without prior chemotherapy (chemo).**

Genitourinary Cancer—Prostate, Testicular, and Penile

**Author(s)** William Kevin Kelly...**Russell Zelig Szmulewitz**...Guru Sonpavde.

**Abstract / POSTER** 5540 • 121

**Session: Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).**

Lung Cancer—Non-Small Cell Metastatic

**Author(s)** Mary Weber Redman...**Everett E. Vokes**...Roy S. Herbst.

**Abstract / POSTER** 9576 • 342

**Session: Personalized viral-based prime/boost immunotherapy targeting patient-specific or shared neoantigens: Immunogenicity, safety, and efficacy results from two ongoing phase I studies.**

Developmental Therapeutics—Immunotherapy

**Author(s)** Charles G. Drake...**Chih-Yi Liao**...**Daniel V.T. Catenacci**.

**Abstract / POSTER** 3137 • 201

**Session: Phase I study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting DLL3, in patients with small cell lung cancer (SCLC).**

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

**Author(s)** Taofeek Kunle Owonikoko...**Everett E. Vokes**...Marie-Anne Damiette Smit.

**Abstract / POSTER** TPS9080 • 273

**Session: AFT-16: Phase II trial of atezolizumab before and after definitive chemoradiation (CRT) for unresectable stage III non-small cell lung cancer (NSCLC).**

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

**Author(s)** Helen J. Ross...**Everett E. Vokes**, Tom Stinchcombe.

**Abstract / POSTER** 9045 • 238